Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Passage BIO, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 51 | 45 | −6 |
| Shares | 40.3M | 40.3M | −25.6K (−0.1%) |
| Value | $54.4M | $32.0M | −$22.4M (−41.2%) |
New holders (3)
Institutions that held Passage BIO, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 1,146 | $910 | 0.00% |
| Global Retirement Partners, LLC | 400 | $318 | 0.00% |
| Harbour Investments, Inc. | 60 | $48 | 0.00% |
Sold out (9)
Institutions that held Passage BIO, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Two Sigma Advisers, LP | 209,600 | $283.0K |
| Pale Fire Capital SE | 141,435 | $190.9K |
| Virtu Financial LLC | 25,425 | $34.0K |
| Marshall Wace, LLP | 21,990 | $29.7K |
| Cubist Systematic Strategies, LLC | 11,290 | $15.2K |
| Citigroup Inc | 3,969 | $5.36K |
| Wells Fargo & Company | 309 | $417 |
| Advisor Group Holdings, Inc. | 217 | $293 |
| Federation des caisses Desjardins du Quebec | 10 | $14 |